Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Akrimax Pharmaceuticals, LLC, Introduces NitroMist® (Nitroglycerin Lingual Aerosol) 400mcg/Spray

March 16, 2011 By Bio-Medicine.Org

CRANFORD, N.J., March 16, 2011 /PRNewswire/ — Coronary artery
disease (CAD), also known as coronary heart disease, is the most
common type of heart disease, currently affecting about 17 million
Americans(1). Most of these people suffer from a common symptom of
CAD known as angina pectoris. For over 100 years, physicians have
treated acute angina with nitrates, the most common form being
nitroglycerin(2). Considered the gold standard in treating acute
angina, nitroglycerin tablets have had problems with diminished
stability and potency once dispensed(3-5). In recent years,
nitroglycerin sprays were introduced and have alleviated much of
the potency and stability concerns associated with the storage of
tablets. Studies have shown that nitroglycerin sprays are capable
of providing a more rapid form of symptom relief in most angina
patients(6).

NitroMist® (Nitroglycerin
Lingual Aerosol 400 mcg) is indicated for acute relief of an attack
or acute prophylaxis of angina pectoris due to coronary artery
disease. It provides nitroglycerin in a rapidly absorbed,
mentholated spray formulation, specifically designed for use on or
under the tongue. NitroMist is available in a fully sealed aerosol
delivery system, providing a shelf life of 36 months. NitroMist
contains no ethyl alcohol.

Nitroglycerin sprays are proven to relieve the symptoms of
angina significantly faster than tablets in most patients(6).

Wayne Anderson, Akrimax’ President and CEO stated, “Akrimax is
committed to providing health care providers and their patients
with therapies that can make an important difference in the lives
of patients. We believe NitroMist is an excellent example of this.
NitroMist is the second new product that Akrimax has brought to
market in the past year. Akrimax also has expanded its sales force
by a third in order to educate health care providers about
NitroMist and its other promoted brands, Tirosint and Inderal
LA.

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech